AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update

by Barry101 | Feb 29, 2024 | Press Release

Company continues progress across Ampligen® clinical development programs Growing body of promising data demonstrates Ampligen’s potential to address multiple high-value indications OCALA, Fla., Feb. 29, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM)...

AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

by Barry101 | Feb 14, 2024 | Press Release

Phase 1b portion of the study expected to be completed within six monthsOCALA, Fla., Feb. 14, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the first subject has been dosed at Erasmus Medical...

AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

by Barry101 | Feb 8, 2024 | Press Release

Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is generally well tolerated in the treatment of Post-COVID Conditions OCALA, Fla., Feb. 08, 2024 — AIM ImmunoTech...

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer

by Barry101 | Jan 24, 2024 | Press Release

Subject enrollment is expected in Q1 2024OCALA, Fla., Jan. 24, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has received authorization from the Erasmus Medical Center (“Erasmus...

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer

by Barry101 | Jan 22, 2024 | Press Release

First enrollment takes place at Erasmus Medical Center in Rotterdam, NetherlandsOCALA, Fla., Jan. 22, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first subject has been enrolled at...